TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $284,151.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) Director Stephanie Lovell sold 4,900 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $57.99, for a total value of $284,151.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

TransMedics Group Price Performance

Shares of TMDX opened at $59.84 on Friday. The company has a quick ratio of 11.21, a current ratio of 12.11 and a debt-to-equity ratio of 0.31. TransMedics Group, Inc. has a 1 year low of $10.00 and a 1 year high of $60.91. The company has a 50 day simple moving average of $47.92 and a two-hundred day simple moving average of $40.82.

TransMedics Group (NASDAQ:TMDXGet Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.15. TransMedics Group had a negative net margin of 58.78% and a negative return on equity of 46.03%. The firm had revenue of $25.68 million during the quarter, compared to analyst estimates of $18.96 million. Sell-side analysts anticipate that TransMedics Group, Inc. will post -1.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC grew its holdings in shares of TransMedics Group by 3.0% in the second quarter. Nisa Investment Advisors LLC now owns 15,550 shares of the company’s stock valued at $489,000 after purchasing an additional 450 shares in the last quarter. Park Avenue Securities LLC lifted its position in TransMedics Group by 3.3% in the second quarter. Park Avenue Securities LLC now owns 17,505 shares of the company’s stock worth $551,000 after buying an additional 560 shares during the last quarter. Legal & General Group Plc lifted its position in TransMedics Group by 4.9% in the second quarter. Legal & General Group Plc now owns 13,502 shares of the company’s stock worth $425,000 after buying an additional 631 shares during the last quarter. Amalgamated Bank lifted its position in TransMedics Group by 17.2% in the third quarter. Amalgamated Bank now owns 4,935 shares of the company’s stock worth $206,000 after buying an additional 725 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in shares of TransMedics Group by 13.2% during the third quarter. Arizona State Retirement System now owns 8,092 shares of the company’s stock worth $338,000 after purchasing an additional 943 shares during the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on TMDX. JPMorgan Chase & Co. upgraded shares of TransMedics Group from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Morgan Stanley upped their price target on shares of TransMedics Group from $45.00 to $54.00 and gave the stock an “equal weight” rating in a report on Friday, November 4th. Cowen raised their price target on shares of TransMedics Group from $45.00 to $50.00 in a report on Tuesday, August 2nd. Finally, Oppenheimer raised their price target on shares of TransMedics Group from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.14.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.